Theriva Biologics (NYSEAMERICAN:TOVX) Shares Down 1.4% – Should You Sell?

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX)’s stock price dropped 1.4% during mid-day trading on Monday . The company traded as low as $1.10 and last traded at $1.20. Approximately 19,166 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 1,002,475 shares. The stock had previously closed at $1.22.

Theriva Biologics Price Performance

The business’s 50-day moving average is $1.42. The stock has a market cap of $3.34 million, a price-to-earnings ratio of -0.04 and a beta of 1.22.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Theriva Biologics stock. Anson Funds Management LP bought a new position in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 139,046 shares of the company’s stock, valued at approximately $192,000. Anson Funds Management LP owned approximately 6.13% of Theriva Biologics as of its most recent SEC filing. 6.17% of the stock is currently owned by institutional investors and hedge funds.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.